Table 2 Adverse events within the first 4 weeks after GD2-specific 4SCAR-T cell infusion
From: Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma
Adverse Event | No. of Patients (n = 8) | Adverse Event | No. of Patients (n = 8) | ||||
|---|---|---|---|---|---|---|---|
Garde 2 | Grade 3 | Grade 4 | Garde 2 | Grade 3 | Grade 4 | ||
Probably related | Â | Â | Â | Respiratory | Â | Â | Â |
Central nervous system | 0 | 0 | 0 | Atelectasis | 0 | 0 | 0 |
Headache | 0 | 1 | 0 | Pain | Â | Â | Â |
Seizure | 1 | 0 | 0 | Extremity | 0 | 0 | 0 |
Unrelated | Â | Â | Â | Bone | 0 | 0 | 0 |
Hematologic toxic | Â | Â | Â | Myalgia | 4 | 1 | 0 |
Anemia | 2 | 0 | 0 | Musculoskeletal | Â | Â | Â |
Lymphopenia | 4 | 1 | 0 | Edema, localized | 0 | 0 | 0 |
Neutropenia | 5 | 0 | 0 | Fracture | 0 | 0 | 0 |
Thrombocytopenia | 0 | 0 | 0 | Central nervous system | Â | Â | Â |
Nonhematologic toxic | Â | Â | Â | Headache | 1 | 1 | 0 |
General | Â | Â | Â | Seizure | 0 | 0 | 0 |
Anorexia | 0 | 0 | 0 | Gait disturbance | 0 | 0 | 0 |
Fatigue | 1 | 0 | 0 | Memory impairment | 0 | 0 | 0 |
Somnolence | 1 | 0 | 0 | Tremors | 0 | 0 | 0 |
Weakness | 1 | 0 | 0 | Cerebral edema | 0 | 0 | 0 |
HEENT | Â | Â | Â | Hydrocephalus | 0 | 0 | 0 |
Eye paralysis, lateral | 0 | 0 | 0 | Infectious | Â | Â | Â |
Gastrointestinal | Â | Â | Â | Urinary tract infection | 0 | 0 | 0 |
Nausea | 0 | 0 | 0 | Laboratory test results | Â | Â | Â |
Diarrhea | 0 | 0 | 0 | Elevated ALT | 0 | 0 | 0 |
Constipation | 0 | 0 | 0 | Elevated AST | 0 | 0 | 0 |
Vomiting | 0 | 0 | 0 | Hyperbilirubinemia | 0 | 0 | 0 |
Cardiac | Â | Â | Â | Hyperkalemia | 0 | 0 | 0 |
Bradycardia | 0 | 0 | 0 | Hypernatremia | 0 | 0 | 0 |
| Â | Â | Â | Â | Hyponatremia | 0 | 0 | 0 |